Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury (2011)
- Authors:
- Autor USP: HOFF, PAULO MARCELO GEHM - FM
- Unidade: FM
- DOI: 10.1200/JCO.2009.27.5701
- Subjects: BIOMARCADORES; FÍGADO (LESÕES;FISIOPATOLOGIA); HEPATOPATIAS (FISIOPATOLOGIA;ETIOLOGIA;COMPLICAÇÕES); MEDICAMENTO (EFEITOS ADVERSOS)
- Language: Inglês
- Imprenta:
- Source:
- Título: Journal of clinical oncology
- ISSN: 0066-782X
- Volume/Número/Paginação/Ano: v. 28, n. 14, p. 2549-2555, 2011
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
OVERMAN, Michael J et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. Journal of clinical oncology, v. 28, n. 14, p. 2549-2555, 2011Tradução . . Disponível em: https://doi.org/10.1200/JCO.2009.27.5701. Acesso em: 24 fev. 2026. -
APA
Overman, M. J., Maru, D. M., Charnsangavej, C., Loyer, E. M., Wang, H., Oathak, P., et al. (2011). Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. Journal of clinical oncology, 28( 14), 2549-2555. doi:10.1200/JCO.2009.27.5701 -
NLM
Overman MJ, Maru DM, Charnsangavej C, Loyer EM, Wang H, Oathak P, Eng C, Hoff PMG, Vauthey J-N, Wolff R a, Kopetz S. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury [Internet]. Journal of clinical oncology. 2011 ; 28( 14): 2549-2555.[citado 2026 fev. 24 ] Available from: https://doi.org/10.1200/JCO.2009.27.5701 -
Vancouver
Overman MJ, Maru DM, Charnsangavej C, Loyer EM, Wang H, Oathak P, Eng C, Hoff PMG, Vauthey J-N, Wolff R a, Kopetz S. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury [Internet]. Journal of clinical oncology. 2011 ; 28( 14): 2549-2555.[citado 2026 fev. 24 ] Available from: https://doi.org/10.1200/JCO.2009.27.5701 - Should patients with advanced colorectal cancer and ECOG 3/4 be treated with chemotherapy?
- Primary prevention of colorectal cancer: Myth or reality?
- Drogas moleculares
- Perspectivas no cuidado dos tumores gastrointestinais
- Obesidade e câncer
- Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors
- Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer
- Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group
- Lack of association between ERCC1 expression in biliary tract malignancy and response to chemotherapy
- Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas
Informações sobre o DOI: 10.1200/JCO.2009.27.5701 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
